CytomX and Regeneron expand collaboration; CytomX to receive $37M in target nomination payments

CytomX Therapeutics, Inc.

Amendment No. 4 adds up to eight new collaboration programs; Regeneron nominates first two.
CytomX receives $37M aggregate target nomination payments for the two nominated programs.
Total potential milestones under expanded agreement are up to approximately $4 billion.
Royalty rates on global net sales unchanged; program selection period extended.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CytomX Therapeutics, Inc. amended Amendment No. 4 with Regeneron Pharmaceuticals, Inc. valued at Total potential target nomination payments and preclinical, clinical, regulatory and commercial mile (effective 2026-05-31).

Action: amendment
Agreement: collaboration
Counterparty: Regeneron Pharmaceuticals, Inc.
Value: Total potential target nomination payments and preclinical, clinical, regulatory and commercial mile
Effective: 2026-05-31

Exact text from the filing

On May 29, 2026, the Company and Regeneron entered into Amendment No. 4 to the Agreement (“Amendment No. 4”), effective May 31, 2026

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-255467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.